What are the benefits of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency?
A 2015 study by Ponikowski et al. concluded that long-term intravenous iron therapy with ferric carboxymaltose was beneficial in patients with symptomatic heart failure and iron deficiency. This study found that it improved patient outcomes such as exercise capacity, quality of life, and biomarkers of iron status. Additionally, it was found to reduce hospital admissions and the need for intravenous diuretics. This suggests that this therapy may be a beneficial option for treating patients with symptomatic heart failure and iron deficiency.  